Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Has MET met its match?

Literature DB >> 27047956

Has MET met its match?

Alain Borczuk¹, Daniel Paucar¹, Balazs Halmos¹.

Abstract

Year: 2016 PMID： 27047956 PMCID： PMC4791336 DOI： 10.21037/atm.2016.01.15

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

30 in total

1. CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors: Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal: Genes Dev Date: 2002-12-01 Impact factor: 11.361

2. MET-Mutated NSCLC with Major Response to Crizotinib.

Authors: Melody A Mendenhall; Jonathan W Goldman
Journal: J Thorac Oncol Date: 2015-05 Impact factor: 15.609

3. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.

Authors: L Schmidt; K Junker; G Weirich; G Glenn; P Choyke; I Lubensky; Z Zhuang; M Jeffers; G Vande Woude; H Neumann; M Walther; W M Linehan; B Zbar
Journal: Cancer Res Date: 1998-04-15 Impact factor: 12.701

4. MET Mutation Associated with Responsiveness to Crizotinib.

Authors: Saiama N Waqar; Daniel Morgensztern; Jennifer Sehn
Journal: J Thorac Oncol Date: 2015-05 Impact factor: 15.609

5. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors: L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal: Nat Genet Date: 1997-05 Impact factor: 38.330

6. Molecular cloning of a new transforming gene from a chemically transformed human cell line.

Authors: C S Cooper; M Park; D G Blair; M A Tainsky; K Huebner; C M Croce; G F Vande Woude
Journal: Nature Date: 1984 Sep 6-11 Impact factor: 49.962

7. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Authors: Jochen K Lennerz; Eunice L Kwak; Allison Ackerman; Michael Michael; Stephen B Fox; Kristin Bergethon; Gregory Y Lauwers; James G Christensen; Keith D Wilner; Daniel A Haber; Ravi Salgia; Yung-Jue Bang; Jeffrey W Clark; Benjamin J Solomon; A John Iafrate
Journal: J Clin Oncol Date: 2011-10-31 Impact factor: 44.544

8. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.

Authors: Philipp Jurmeister; Dido Lenze; Erika Berg; Stefanie Mende; Frank Schäper; Udo Kellner; Hermann Herbst; Christine Sers; Jan Budczies; Manfred Dietel; Michael Hummel; Maximilian von Laffert
Journal: Lung Cancer Date: 2014-12-06 Impact factor: 5.705

9. Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon.

Authors: E M Powell; W M Mars; P Levitt
Journal: Neuron Date: 2001-04 Impact factor: 17.173

10. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.

Authors: David R Spigel; Martin J Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; Wei Yu; Karen Rittweger; Holger Thurm
Journal: Clin Lung Cancer Date: 2012-11 Impact factor: 4.785

3 in total